Schwab Charles Investment Management Inc. lowered its holdings in PAREXEL International Corporation (NASDAQ:PRXL) by 23.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 350,368 shares of the medical research company’s stock after selling 109,813 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.69% of PAREXEL International Corporation worth $30,451,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Trexquant Investment LP acquired a new stake in PAREXEL International Corporation in the 2nd quarter valued at approximately $973,000. Global X Management Co. LLC grew its holdings in PAREXEL International Corporation by 17.9% in the 2nd quarter. Global X Management Co. LLC now owns 4,892 shares of the medical research company’s stock valued at $425,000 after buying an additional 742 shares during the last quarter. ARP Americas LLC acquired a new stake in PAREXEL International Corporation in the 2nd quarter valued at approximately $15,958,000. Sei Investments Co. grew its holdings in PAREXEL International Corporation by 9.9% in the 2nd quarter. Sei Investments Co. now owns 47,366 shares of the medical research company’s stock valued at $4,116,000 after buying an additional 4,253 shares during the last quarter. Finally, Texas Permanent School Fund grew its holdings in PAREXEL International Corporation by 0.5% in the 2nd quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock valued at $3,221,000 after buying an additional 169 shares during the last quarter. 87.48% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “PAREXEL International Corporation (PRXL) Shares Sold by Schwab Charles Investment Management Inc.” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/14/parexel-international-corporation-prxl-shares-sold-by-schwab-charles-investment-management-inc.html.

Several analysts have recently weighed in on PRXL shares. Zacks Investment Research lowered PAREXEL International Corporation from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Credit Suisse Group reissued a “neutral” rating and set a $83.00 price objective (up previously from $65.00) on shares of PAREXEL International Corporation in a report on Tuesday, June 6th. Mizuho lifted their price objective on PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, May 30th. BidaskClub lowered PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Goldman Sachs Group, Inc. (The) raised PAREXEL International Corporation from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $63.00 to $77.00 in a report on Tuesday, May 23rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. PAREXEL International Corporation currently has an average rating of “Hold” and an average target price of $75.92.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) opened at 87.93 on Thursday. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 42.68 and a beta of 0.79. The company has a 50-day moving average price of $87.67 and a 200 day moving average price of $77.32. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.98.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same quarter last year, the company earned $0.94 earnings per share. Analysts expect that PAREXEL International Corporation will post $3.95 EPS for the current fiscal year.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.